Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: sitagliptin 100 mg and metformin 2000 mg.
This medication is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually.
The starting dose of this medication should be determined according to the patient's current treatment regimen.
1. Patients not currently treated with metformin:
For patients with no prior experience with antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the starting dose is 1 tablet of this medication 50/500 mg twice daily. The dose may be increased to 1 tablet of this medication 50/1000 mg twice daily.
Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Patients Who Must Not Receive This Medication).
2. Patients receiving metformin:
- For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended starting dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose.
- Patients switching to this medication from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin.
3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione:
The starting dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg); the starting dose of metformin should take into account the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions).
No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral glucose-lowering medication to this medication. Any change in the treatment regimen for type 2 diabetes may cause a change in glycemic control; therefore, caution and appropriate monitoring are required.
Patients with renal impairment
This medication may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who have no other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment.
Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months.
If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication must be discontinued immediately.
Patients with hepatic impairment
This medication must not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Receive This Medication).
Improvement of glycemic control in patients with type 2 diabetes mellitus
View approved original textHide original text
This medication is used to assist patients with type 2 diabetes in controlling their blood sugar when combined with dietary and exercise regimens. Sitagliptin and metformin work together to effectively regulate blood sugar and help the patient's health management.
How to take
Adult dose
For antidiabetic therapy, the dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: sitagliptin 100 mg and metformin 2000 mg.
This medication is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually.
The starting dose of this medication should be determined according to the patient's current treatment regimen.
1. Patients not currently treated with metformin:
For patients with no prior experience with antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the starting dose is 1 tablet of this medication 50/500 mg twice daily. The dose may be increased to 1 tablet of this medication 50/1000 mg twice daily.
Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Patients Who Must Not Receive This Medication).
2. Patients receiving metformin:
- For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended starting dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose.
- Patients switching to this medication from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin.
3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione:
The starting dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg); the starting dose of metformin should take into account the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions).
No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral glucose-lowering medication to this medication. Any change in the treatment regimen for type 2 diabetes may cause a change in glycemic control; therefore, caution and appropriate monitoring are required.
Patients with renal impairment
This medication may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who have no other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment.
Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months.
If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication must be discontinued immediately.
Patients with hepatic impairment
This medication must not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Receive This Medication).
Precautions
This medication consists of two components, each with different precautions.
First, the sitagliptin component can cause serious allergic reactions, although they are rare. Such reactions can include skin rashes, angioedema, and severe skin disorders, and may occur within the first three months of taking the medication, so careful monitoring is necessary. If such symptoms are suspected, immediately discontinue the medication and consult a physician.
Additionally, sitagliptin can trigger acute pancreatitis, so if abdominal pain or vomiting occurs during treatment, inform healthcare providers immediately.
The metformin component can cause lactic acidosis, a rare but fatal metabolic disorder, so patients with impaired kidney function or liver problems should not use this medication. Moreover, patients in conditions that can affect kidney function, such as dehydration, severe infections, heart failure, or acute myocardial infarction, should also avoid this medication.
This medication should be used with regular monitoring of kidney function, especially for the elderly or patients with impaired renal function, who need to be checked more frequently. If kidney function is severely impaired, the medication should be discontinued.
Furthermore, if undergoing acute surgery or radiological testing during the use of this medication, the medication should be temporarily paused before and after tests, and resumed only after confirming normal kidney function.
There is also a risk of hypoglycemia, so particular caution is needed for those taking this medication alongside other hypoglycemic agents such as insulin or sulfonylureas. If symptoms arise, appropriate measures should be taken immediately.
Pregnant or potentially pregnant women and nursing mothers should not take this medication, and safety for children under 18 has not been established.
It is advisable to avoid alcohol consumption during treatment, as excessive drinking may elevate the risk of lactic acidosis.
Finally, if any abnormal symptoms or side effects occur while taking this medication, promptly consult a doctor, and ensure regular blood tests and kidney function checks to manage health status.
Not everyone experiences these, and they can vary from person to person.
Storage
This medication should be stored in a tightly sealed container to prevent air exposure, at room temperature between 1 degree and 30 degrees.
Storing it this way helps maintain its efficacy and prevent degradation.
Appearance and packaging
Appearance
Brown oval film-coated tablet
Package unit
60 tablets/box [10 tablets/PTP x 6]
Same-ingredient medicines
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.